Entera Bio (ENTX) Non-Current Assets (2017 - 2026)
Entera Bio (ENTX) posted quarterly Non-Current Assets of $636000.0 for Q1 2026, up 66.49% year-on-year from $382000.0 in Q1 2025, and down 8.49% on a QoQ basis from $695000.0 in Q4 2025.
Entera Bio (ENTX) Non-Current Assets (2017 - 2026) Analysis & Trends
Entera Bio (ENTX) has reported Non-Current Assets for 10 consecutive years, with $636000.0 the latest figure, recorded in Q1 2026.
- Quarterly Non-Current Assets rose 66.49% year-over-year to $636000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $636000.0 (up 66.49% YoY) and the FY2025 annual result came in at $695000.0, up 66.27% from the prior year.
- Non-Current Assets retreated to $636000.0 in Q1 2026 per ENTX's latest filing, from $695000.0 in the prior quarter.
- Over the last five years, Non-Current Assets for ENTX reached as high as $695000.0 in Q4 2025 and fell as low as $233000.0 in Q1 2023.
- A 5-year average of $476352.9 and a median of $440000.0 in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets slumped 65.28% — and 2024, when it soared 109.44%.
- Year by year, Non-Current Assets stood at $278000.0 in 2022, then surged by 82.73% to $508000.0 in 2023, then retreated by 17.72% to $418000.0 in 2024, then surged by 66.27% to $695000.0 in 2025, then slipped by 8.49% to $636000.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $636000.0, $695000.0, and $400000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 5.83 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.95 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 285.82 Mn |
| 10 | Entera Bio | 186.78 Mn | 182.64 Mn | - | 636,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 636,000.00 |
| Dec 31, 2025 | 695,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 356,000.00 |
| Mar 31, 2025 | 382,000.00 |
| Dec 31, 2024 | 418,000.00 |
| Sep 30, 2024 | 401,000.00 |
| Jun 30, 2024 | 440,000.00 |
| Mar 31, 2024 | 488,000.00 |
| Dec 31, 2023 | 508,000.00 |
| Sep 30, 2023 | 549,000.00 |
| Jun 30, 2023 | 631,000.00 |
| Mar 31, 2023 | 233,000.00 |
| Dec 31, 2022 | 278,000.00 |
| Sep 30, 2022 | 350,000.00 |
| Jun 30, 2022 | 662,000.00 |
| Mar 31, 2022 | 671,000.00 |
| Dec 31, 2021 | 658,000.00 |
| Jun 30, 2021 | 1.03 Mn |
| Dec 31, 2020 | 613,000.00 |